233 related articles for article (PubMed ID: 27836119)
41. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
[TBL] [Abstract][Full Text] [Related]
42. Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes.
Yang ZR; Zhao N; Meng J; Shi ZL; Li BX; Wu XW; Li P; Zhang Q; Wei XB; Fu S
Oncotarget; 2016 May; 7(18):26422-35. PubMed ID: 27029063
[TBL] [Abstract][Full Text] [Related]
43. Health Technology Assessment of Carbon-ion Beam Radiotherapy: A Systematic Review of Clinical Effectiveness and Safety for 54 Oncological Indications in 12 Tumour Regions.
Goetz G; Mitic M; Mittermayr T; Wild C
Anticancer Res; 2019 Apr; 39(4):1635-1650. PubMed ID: 30952702
[TBL] [Abstract][Full Text] [Related]
44. Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Haruyama Y; Kobashi G; Ebner DK; Akakura K; Suzuki H; Ichikawa T; Shimazaki J; Makishima H; Nomiya T; Kamada T; Tsujii H;
Cancer Sci; 2017 Dec; 108(12):2422-2429. PubMed ID: 28921785
[TBL] [Abstract][Full Text] [Related]
45. Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN).
Koto M; Demizu Y; Saitoh JI; Suefuji H; Tsuji H; Okimoto T; Ohno T; Shioyama Y; Takagi R; Nemoto K; Nakano T; Kamada T;
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1054-1060. PubMed ID: 28332989
[TBL] [Abstract][Full Text] [Related]
46. A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas: Subanalysis of J-CROS 1402 HN.
Hayashi K; Koto M; Demizu Y; Saitoh JI; Suefuji H; Okimoto T; Ohno T; Shioyama Y; Takagi R; Ikawa H; Nemoto K; Nakano T; Kamada T;
Cancer Sci; 2018 May; 109(5):1576-1582. PubMed ID: 29493851
[TBL] [Abstract][Full Text] [Related]
47. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact.
Garibaldi E; Gabriele D; Maggio A; Delmastro E; Garibaldi M; Bresciani S; Ortega C; Stasi M; Gabriele P
Panminerva Med; 2016 Jun; 58(2):121-9. PubMed ID: 26785374
[TBL] [Abstract][Full Text] [Related]
48. A multi-institutional retrospective study of carbon-ion radiotherapy for non-squamous cell malignant tumors of the nasopharynx: Subanalysis of Japan Carbon-Ion Radiation Oncology Study Group study 1402 HN.
Abe T; Ohno T; Koto M; Demizu Y; Suefuji H; Tsuji H; Okimoto T; Shioyama Y; Saitoh JI; Shirai K; Nemoto K; Nakano T; Kamada T;
Cancer Med; 2018 Dec; 7(12):6077-6083. PubMed ID: 30449067
[TBL] [Abstract][Full Text] [Related]
49. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26].
Gottschalk A
Urol Oncol; 2014 Apr; 32(3):374. PubMed ID: 24679464
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning.
El Shafie RA; Czech M; Kessel KA; Habermehl D; Weber D; Rieken S; Bougatf N; Jäkel O; Debus J; Combs SE
Radiat Oncol; 2018 Mar; 13(1):54. PubMed ID: 29587795
[TBL] [Abstract][Full Text] [Related]
51. Radiotherapy for early-stage prostate cancer in men under 70 years of age.
Bellavita R; Scricciolo M; Bini V; Arcidiacono F; Montesi G; Lancellotta V; Zucchetti C; Lupattelli M; Palumbo I; Aristei C
Tumori; 2016; 102(2):209-16. PubMed ID: 26429649
[TBL] [Abstract][Full Text] [Related]
52. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
[TBL] [Abstract][Full Text] [Related]
53. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities.
Nihei K; Ogino T; Onozawa M; Murayama S; Fuji H; Murakami M; Hishikawa Y
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):390-6. PubMed ID: 20832180
[TBL] [Abstract][Full Text] [Related]
54. Carbon-ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS).
Shiba S; Wakatsuki M; Toyama S; Terashima K; Uchida H; Katoh H; Shibuya K; Okazaki S; Miyasaka Y; Ohno T; Tsuji H
Cancer Sci; 2023 Sep; 114(9):3679-3686. PubMed ID: 37391921
[TBL] [Abstract][Full Text] [Related]
55. Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis.
Nakajima M; Yamamoto N; Hayashi K; Karube M; Ebner DK; Takahashi W; Anzai M; Tsushima K; Tada Y; Tatsumi K; Miyamoto T; Tsuji H; Fujisawa T; Kamada T
Radiat Oncol; 2017 Sep; 12(1):144. PubMed ID: 28865463
[TBL] [Abstract][Full Text] [Related]
56. First prospective feasibility study of carbon-ion radiotherapy using compact superconducting rotating gantry.
Bhattacharyya T; Koto M; Ikawa H; Hayashi K; Hagiwara Y; Makishima H; Kasuya G; Yamamoto N; Kamada T; Tsuji H
Br J Radiol; 2019 Nov; 92(1103):20190370. PubMed ID: 31317764
[TBL] [Abstract][Full Text] [Related]
57. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
58. Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Li M; Li X; Yao L; Han X; Yan W; Liu Y; Fu Y; Wang Y; Huang M; Zhang Q; Wang X; Yang K
Front Oncol; 2021; 11():709530. PubMed ID: 34712607
[TBL] [Abstract][Full Text] [Related]
59. Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG).
Kubo N; Suefuji H; Nakajima M; Tokumaru S; Okano N; Yoshida D; Suzuki O; Ishikawa H; Satouchi M; Nakayama H; Shimizu K; Shioyama Y
J Thorac Oncol; 2024 Mar; 19(3):491-499. PubMed ID: 37924974
[TBL] [Abstract][Full Text] [Related]
60. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
